Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)

Inclusion Criteria:

* Primary urinary bladder tumor
* Secondary urinary bladder tumor (recurrence)
* Bipolar or monopolar resection
* Creat \<2.2mg/dl
* 35% \<Hct \<52%
* White bloode cells count WBC ≥3000 / μL
* 75000 \<PLT \<500000 / μL
* Urine culture: negative / sterile
* Alkaline phosphatase, total bilirubin, SGOT, SGPT: values as high as 2 times above the upper normal limit
* Good clinical condition (according to Eastern Cooperative Oncology Group PS ≤ 1)
* CT Urography without findings suggesting an upper urinary tract tumor in the last 3 months before the transurethral resection of the bladder tumor

Exclusion Criteria:

* More than 2 low grade / high differentiation (low grade / LG) histologically confirmed bladder tumors in the last 18 months before the transurethral resection of the bladder tumor
* High grade / low differentiation (HG) histologically confirmed bladder tumor in the last 9 months before the transurethral resection of the bladder tumor
* Those who undergo a transurethral resection of a bladder tumor according to the Guidelines of the European Association of Urology for non-muscle-invasive bladder cancer: incomplete resection of tumor, absence of muscle fibers in the sample with the exception of: Ta / LG-G1, primary Cis and finally, pT1 tumors
* Intravesical instillation of chemotherapeutic agent or BCG in the last 6 months before the transurethral resection of the bladder tumor
* History of non-urothelial bladder cancer
* Stage of disease pT2 (muscle-invasive bladder cancer)
* Presence of a tumor in the urethra
* Upper urinary tract malignancy (present or anamnestically)
* History of pelvic radiotherapy
* Histrory of another malignancy in the last 5 years before the transurethral resection of the bladder tumor